Clinical Trial Update: Arsenous Acid for Refractory Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating arsenous acid for refractory triple-negative breast cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Arsenous acid (arsenous acid)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING